Secured the first-ever CDMO manufacturing and supply agreement for a rare premium fragrance, significantly ahead of the previously outlined schedule. Transitioning strategy from proving the breadth of Botanical Synthesis applications to selectively converting high-value opportunities into recurring manufacturing revenue and royalties. Reallocated capital and management focus from the direct-to-consumer (D2C) business toward manufacturing capacity build-out and the growing CDMO division. Attributed the D2C revenue guidance reduction to deliberate spending discipline in response to double-digit media inflation on platforms like Meta. Leveraging existing developed molecules (olive, pomegranate, blueberry) as CDMO assets to accelerate time-to-market for strategic partners.